Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix^®) in adults 55 years of age and over: A sub-analysis of four trialsVAN DAMME, Pierre; MCINTYRE, Peter; GRIMPREL, Emmanuel et al.Vaccine. 2011, Vol 29, Num 35, pp 5932-5939, issn 0264-410X, 8 p.Article

Gene Polymorphism in Toll-like Receptor 4: Effect on Antibody Production and Persistence After Acellular Pertussis Vaccination During AdolescenceGRÖNDAHL-YLI-HANNUKSELA, Kirsi; VUONONVIRTA, Juho; BARKOFF, Alex-Mikael et al.The Journal of infectious diseases. 2012, Vol 205, Num 8, pp 1214-1219, issn 0022-1899, 6 p.Article

EFFECT OF A PREPREGNANCY PERTUSSIS BOOSTER DOSE ON MATERNAL ANTIBODY TITERS IN YOUNG INFANTSLEURIDAN, Elke; HENS, Niel; PEETERS, Natasja et al.The Pediatric infectious disease journal. 2011, Vol 30, Num 7, pp 608-610, issn 0891-3668, 3 p.Article

A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adultsBOOY, Robert; VAN DER MEEREN, Olivier; NG, Su-Peing et al.Vaccine. 2010, Vol 29, Num 1, pp 45-50, issn 0264-410X, 6 p.Article

Phase II Study of a Three-dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-month Hib-MenC-TT Booster in Healthy InfantsKHATAMI, Ameneh; SNAPE, Matthew D; CAUBET, Magalie et al.The Pediatric infectious disease journal. 2013, Vol 32, Num 6, pp 675-681, issn 0891-3668, 7 p.Article

Decennial Administration of a Reduced Antigen Content Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine in Young AdultsMERTSOLA, Jussi; VAN DER MEEREN, Olivier; QIUSHUI HE et al.Clinical infectious diseases. 2010, Vol 51, Num 6, pp 656-662, issn 1058-4838, 7 p.Article

SAFETY AND REACTOGENICITY OF DTPA-HBV-IPV/HIB AND DTPA-IPV/HIB VACCINES IN A POST-MARKETING SURVEILLANCE SETTINGFONG SENG LIM; KONG BOO PHUA; BEE WAH LEE et al.Southeast Asian journal of tropical medicine and public health. 2011, Vol 42, Num 1, pp 138-147, issn 0125-1562, 10 p.Article